Phase 3
Completed N=239
Efficacy of Ginger on Intraoperative and Postoperative Nausea and Vomiting in Elective Cesarean Section Patients
Source: ClinicalTrials.gov NCT01733212 ↗Enrolled (actual)
239
Serious AEs
0.0%
Results posted
May 2018
Primary outcomePrimary: Occurrence of Intra-operative and Post-operative Vomiting — 30; 45 Participants — p=0.07
◆ Published Evidence
Established
45citations · ~3 / year
Efficacy of ginger on intraoperative and postoperative nausea and vomiting in elective cesarean section patients.
Summary
SPECIFIC AIMS
* Assess risk factors for nausea and vomiting in c-section patients undergoing regional anesthesia
* Quantify the incidence of nausea and vomiting intraoperatively and postoperatively in the ginger and placebo groups.
* Quantify post-operative analgesia and pruritus in the ginger and placebo groups
* Quantify patient satisfaction of the ginger and placebo groups
* Assess patient expectation of ginger on post-op day three
Linked Publications (2)
-
Efficacy of ginger on intraoperative and postoperative nausea and vomiting in elective cesarean section patients.
-
Interventions for preventing nausea and vomiting in women undergoing regional anaesthesia for caesarean section.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Occurrence of Intra-operative and Post-operative Vomiting |
30; 45 | 0.07 |
Eligibility Criteria
Inclusion Criteria
- Healthy (i.e., ASA I, or II) patients presenting for planned c-section at New York Methodist Hospital
- Signed informed consent
Exclusion Criteria
- They are unable or unwilling to take part in the study
- They have a history of an allergy to any medications used including ginger
- They have had any gastrointestinal surgery on the stomach, small intestine, or gall bladder.
- They have any history of bleeding disorder, (i.e., Hemophilia A/B, ITP, etc.)
- They have a contraindication to intrathecal or epidural anesthesia. ( i.e., Arnold- Chiari malformation, etc.)
- They are unable to understand instructions or questions related to study
- ASA III or IV patients
Data sourced from ClinicalTrials.gov (NCT01733212) and the linked publication. Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.